A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling
| Autor: | Bálint Szokol, Gábor Németh, Dániel Eros, Stewart T. Cole, Bálint Hegymegi-Barakonyi, György Kéri, István Szabadkai, János Pató, Rita Székely, Bert Klebl, Laszlo Orfi, Jacqueline Satchell, Doris Hafenbradl, Frigyes Wáczek, Brigitte Saint-Joanis |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Immunology
Microbial Sensitivity Tests Thiophenes Biology Protein Serine-Threonine Kinases Mycobacterium tuberculosis Inhibitory Concentration 50 Mice Structure-Activity Relationship Bacterial Proteins Immunology and Allergy Structure–activity relationship Animals Tuberculosis Protein Kinase Inhibitors Cells Cultured Phagosome Cell growth Kinase Drug discovery Macrophages biology.organism_classification Amides Biochemistry Drug Design Pharmacophore Intracellular Signal Transduction |
| Zdroj: | Immunology letters. 116(2) |
| ISSN: | 0165-2478 |
| Popis: | The Mycobacterium tuberculosis genome encodes for eleven eukaryotic-like Ser/Thr protein kinases. At least three of these (PknA, PknB and PknG) are essential for bacterial growth and survival. PknG is secreted by pathogenic mycobacteria, in macrophages to intervene with host cell signalling pathways and to block the fusion of the lysosomes with the phagosome by a still unknown mechanism. Based on our previously published results, we have initiated a drug discovery program, aiming to improve the potency against PknG and the physiochemical properties of the initially identified hit compound, AX20017, from the class of the tetrahydrobenzothiophenes. We have established a radioactive biochemical PknG kinase assay to test the novel analogues around AX20017. We have developed lead molecules with IC50 values in nanomolar range, and demonstrated their antituberculotic effects on human macrophages. Selected leads might ultimately serve the purpose of inducing phagosomal-lysosomal fusion and therefore destroy the residence of the intracellular mycobacteria. It is unclear at this time if these "homeless" mycobacteria are getting killed by the host, but they will be at least vulnerable to the activity of antimycobacterial agents. Released mycobacteria rely on the essential function of PknB for survival, which is our second molecular kinase target. PknB is a transmembrane protein, responsible for the cell growth and morphology. We have screened our library and synthesized novel compounds for the inhibition of PknB. A pharmacophore model was built and 70,000 molecules from our synthesizable virtual library have been screened to identify novel inhibitor scaffolds for the generation of templated compound libraries. Currently, we are using a radioactive kinase assay employing GarA as the putative, physiological substrate of PknB kinase. We have identified hits and generated optimised hit compounds with IC50 values for the inhibition of PknB in the nanomolar range. Yet those promising hits are not potent enough to yield meaningful "minimum inhibitory concentrations" in mycobacterial growth assays. In the course of our future work, we will increase the potency of the next generation of PknB inhibitors in order to improve their antibacterial activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect